Vitamin D deficiencies in HIV management
2 April 2010. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
2010
OCTANE 2: nevirapine and lopinavir/r are similar when used with tenofovir and FTC in treatment-naive women
2 April 2010. Related: Conference reports, Pregnancy.
HIV incidence and retesting in pregnancy
2 April 2010. Related: Conference reports, Pregnancy.
Efavirenz use in pregnancy and birth outcomes
2 April 2010. Related: Conference reports, Pregnancy.
Pregnancy outcomes in women using non-AZT HAART in Europe
2 April 2010. Related: Conference reports, Pregnancy.
When should HAART be initiated in pregnancy to achieve an undetectable viral load?
2 April 2010. Related: Conference reports, Pregnancy.
Pregnancy outcomes in infants exposed to maternal antiretrovirals in utero
2 April 2010. Related: Conference reports, Pregnancy, Paediatric care.
Maternal TB, HIV and pregnancy
2 April 2010. Related: Conference reports, Women's health, Pregnancy, TB coinfection.
Non-refrigerated ritonavir tablet approved in Europe and the US
2 April 2010. Related: Antiretrovirals.
FDA safety review of saquinavir (Invirase) and possible association with abnormal heart rhythms
2 April 2010. Related: Antiretrovirals.
FDA updates US label for darunavir (Prezista)
2 April 2010. Related: Antiretrovirals.
FDA safety announcement about ddI and non-cirrhotic portal hypertension
2 April 2010. Related: Antiretrovirals.
FDA label change for lopinavir/r (Kaletra)
2 April 2010. Related: Antiretrovirals.
FDA notice about drug interactions with etravirine (Intelence)
2 April 2010. Related: Antiretrovirals.
FDA approval of generic ARVs
2 April 2010. Related: Treatment access.
Waiting lists grow in the US
2 April 2010. Related: Treatment access.
South African antiretroviral treatment guidelines (2010)
2 April 2010. Related: Treatment access, Guidelines.
Tenofovir registered in Russia
2 April 2010. Related: Treatment access.
MSF criticise Abbott over new ritonavir formulation
2 April 2010. Related: Treatment access.
BHIVA draft guidelines for the treatment of opportunistic infections (2010): online for comment
2 April 2010. Related: Guidelines, Coinfections and complications, BHIVA news.
Infant feeding in the UK (2010): draft guidelines online for comment
2 April 2010. Related: Pregnancy, Paediatric care, Guidelines.
Legal issues on HIV transmission and the law for healthcare workers: draft guidelines online for comment
2 April 2010. Related: Guidelines, BHIVA news.
Early predictors of disease progression
2 April 2010. Related: Basic science and immunology.
Sex and the single microbicide
2 April 2010. Related: Basic science and immunology.
Baseline naive CD4 T cell numbers predict the immunological response to ART
2 April 2010. Related: Basic science and immunology.
Has poor CD4 T cell reconstitution in the gut been exaggerated?
2 April 2010. Related: Basic science and immunology.
Journal articles
1 April 2010. Related: On the web.
Volume 11 Number 3/4 March/April2010 PDF
1 April 2010. Related: PDFs.
CROI 2010: non technical summary of 12 key areas of research
1 April 2010. Related: Special reports.
CROI 2010: non-technical summary of 12 key areas of research PDF
1 April 2010. Related: PDFs.
Volume 11 Number 1/2 January/February2010
22 February 2010. Related: Editorial.
12th European AIDS Society Conference (EACS), 11-14 November 2009, Cologne
21 February 2010. Related: Conference reports.
Screening for anal cancer recommended for HIV positive men
21 February 2010. Related: Conference reports, Cancer and HIV.
Once-daily darunavir/r monotherapy is suboptimal as initial regimen in treatment-naive people
21 February 2010. Related: Conference reports, Antiretrovirals.
Central fat accumulation remains a significant problem in patients starting HAART after 2005 with higher incidence in women compared to men
21 February 2010. Related: Conference reports, Women's health, Side effects, Lipodystrophy and metabolic complications.
Alendronate improves bone mineral density in HIV positive people with osteoporosis at 96 weeks
21 February 2010. Related: Conference reports, Side effects.
TMC278 did not show teratogenic potential in animal models
21 February 2010. Related: Conference reports, Pregnancy.
Etravirine pregnancy data from five cases: no dose adjustment required
21 February 2010. Related: Conference reports, Pregnancy.
No clinically relevant interactions between TMC278 and oral contraceptives (norethindrone plus ethinylestradiol)
21 February 2010. Related: Conference reports, Women's health, PK and drug interactions.
Gender-based differences in patients receiving antiretroviral therapy
21 February 2010. Related: Conference reports, Women's health.
Pilot PK study of two generic paediatric formulations of lopinavir/ritonavir vs originator products
21 February 2010. Related: Conference reports, Paediatric care, PK and drug interactions.
Other selected PK and drug interaction summaries from EACS
21 February 2010. Related: Conference reports, PK and drug interactions.
11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV (IWADR) 26-28 October 2009, Philadelphia
20 February 2010. Related: Conference reports, Side effects.
The HCV pipeline efficacy and side effect of compounds in Phase 3 studies
20 February 2010. Related: Conference reports, Hepatitis coinfection.
GSK issues Dear Doctor letter in the US: fosamprenavir and cardiovascular risk
16 February 2010. Related: Antiretrovirals, Side effects.
HIV disease and renal function
15 February 2010. Related: Side effects.
Pregnancy not nevirapine associated with risk of hepatotoxicity in large cohort comparison
14 February 2010. Related: Pregnancy.
Birth defects following efavirenz exposure in a South African Hospital
14 February 2010. Related: Pregnancy.
Outcomes from screening study for anal cancer in HIV positive compared to HIV negative patients
10 February 2010. Related: Cancer and HIV.
No interaction between tipranavir/ritonavir and efavirenz
8 February 2010. Related: PK and drug interactions.
Significant interactions between tipranavir/ritonavir and statins
8 February 2010. Related: PK and drug interactions.
Summary of interactions between vivriviroc and other ARVs
8 February 2010. Related: PK and drug interactions.
Significant interaction between atazanavir/ritonavir and the antipsychotic drug quetiapine
8 February 2010. Related: PK and drug interactions.
US guidelines update (2010): treat when CD4 is less than 500 cells/mm3
7 February 2010. Related: Guidelines.
WHO publish major revisions to HIV management guidelines (Nov 2009)
7 February 2010. Related: Guidelines.
Updated paediatric HIV treatment guidelines (PENTA, 2009)
7 February 2010. Related: Guidelines.
FDA approval of generic ARVs
6 February 2010. Related: Treatment access.
UNITAID decision to fund patent pool to boost access to new medicines
6 February 2010. Related: Treatment access.
PEPFAR launches five-year strategy
6 February 2010. Related: Treatment access.
Global Fund approves US$2.4 billion in new grants
6 February 2010. Related: Treatment access.
Early predictors of disease progression
5 February 2010. Related: Basic science and immunology.
Bridging the neurology-immunology barrier
5 February 2010. Related: Basic science and immunology.
Free journal on immunology and cardiovascular disease
5 February 2010. Related: Basic science and immunology.
Male circumcision: new data supporting protective mechanism
4 February 2010. Related: HIV prevention and transmission.
A caution for male circumcision programmes: high complication rates highlighted outside a trial setting
4 February 2010. Related: HIV prevention and transmission.